Concert Pharmaceuticals, Inc. (CNCE) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Roth Keeps Concert Pharma (CNCE) at Buy; Making Good Progress with Clinical Programs
August 12, 2014 3:23 PM EDTRoth Capital affirms Concert Pharmaceuticals (Nasdaq: CNCE) at Buy with a target price of $28 following the company's Q2 results.
Concert reported Q2 loss of $0.45 per share versus Roth's estimated loss of $0.47 per share.
Analyst Joseph Pantginis commented, We believe Concert is making good progress on their clinical programs, both in their in-house and partnered programs. The company's R&D expenses are... More
